



03-01-04

PATENT  
ATTORNEY DOCKET NO. 05032-00032

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Jerome Sohier and Jeroen Mattijs Bezemer

Serial No.: 10/673,041

Filed: September 25, 2003

Title: COATING FOR MEDICAL DEVICES

Examiner:

Art Unit: 1714

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450TRANSMITTAL OF PRIORITY DOCUMENTS

Applicants submit herewith a certified copy of European Patent Application No.01201259.7 and of International Application no. PCT/NL02/00212, from which the above-referenced U.S. patent application claims priority. No fee is due. Please apply any other charges or any credits to Deposit Account No. 19-0733.

Respectfully submitted,

Dated:

February 27, 2004

By

John P. Iwanicki, Reg. No. 34,628  
BANNER & WITCOFF, LTD.  
28 State Street, 28th Floor  
Boston, MA 02109  
(617) 720-9600





**Europäisches  
Patentamt**

**European  
Patent Office**

**Office européen  
des brevets**

**Bescheinigung**

**Certificate**

**Attestation**

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

**Patentanmeldung Nr.    Patent application No.    Demande de brevet n°**

01201259.7

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

**R C van Dijk**

DEN HAAG, DEN  
THE HAGUE,  
LA HAYE, LE

11/02/04





Anmeldung Nr:  
Application no.: 01201259.7  
Demande no:

Anmeldetag:  
Date of filing: 04.04.01  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

IsoTis B.V.  
Prof. Bronkhorstlaan 10  
3723 MB Bilthoven  
PAYS-BAS

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se referer à la description.)

Coating for medical devices

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)  
revendiquée(s)

Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

/00.00.00/

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

A61L29/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of  
filing/Etats contractants désignées lors du dépôt:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR



04. 04. 2001

Title: Coating for medical devices

(45)

The invention relates to a coating for medical devices. The invention further relates to a process for applying a coating to a surface, *e.g.* a surface of a medical device, and to a medical device comprising said coating.

Great effort has been put into studies of coatings for medical devices.

- 5 Materials used for the manufacture of medical devices are not always chosen from a biocompatibility point of view as often other considerations, *e.g.* with respect to strength or tensile and stretching properties, prevail.

Coatings for medical devices are, however, not only interesting for enhancing the biocompatibility of a medical device. They also provide a  
10 possibility to provide a controlled release of biologically active agents, in which case it is necessary that the coating is also biodegradable.

Problems encountered in the design of coatings for medical devices are many. One of the bigger problems concerns the adhesion of the coating to the material of which the medical device is made. As many different materials,  
15 varying from metals to ceramics and polymeric materials, are used for the manufacture of medical devices, it is important that a good coating adheres sufficiently to all sorts of materials. This is, however, often not the case.

Another problem concerns the conditions a medical device is subjected to during use. Certain medical devices, such as catheters, are for  
20 instance subjected to deformation *in vivo*. When the device expands, it is important that the coating is capable of undergoing the same deformation without breaking or coming loose. This would lead to exposure of the surface of the material of the medical device to the surrounding tissue *in vivo*. In the worst case, parts of the coating might detach from the device completely.

25 Accordingly, there is a need for a coating material for medical devices which may be used universally for different sorts of medical devices of different materials.

The invention provides a coating that fulfils this need. A specific copolymer has been found of which the properties may be adjusted to the needs

and requirements of application on a specific medical device of a specific material. Accordingly, the invention relates to a coating for a medical device comprising a copolymer of a polyalkylene glycol terephthalate and an aromatic polyester.

5           A coating according to the invention may be applied to a wide range of materials. It is one of the great advantages of the invention that the composition of the copolymer may be adjusted such as to achieve a good adhesion to nearly any type of material. The nature and molecular weights of the monomers of the copolymer, as well as the ratio of the two monomers and  
10   the molecular weight of the copolymer itself, provide a multitude of variations that can be used to achieve an optimum property profile of a coating. These parameters do not only serve to adjust the adhesion of the coating. Other properties can be optimised as well. Examples of such properties include the degradability and swelling behaviour of the coating and mechanical properties,  
15   like elasticity and tensile strength. Other properties and advantages will become clear from the following, more detailed description of the invention.

          A coating according to the invention comprises a copolymer of a polyalkylene glycol terephthalate and an aromatic polyester. Preferably, the copolymer comprises 20-90 wt.%, more preferably 40-70 wt.% of the  
20   polyalkylene glycol terephthalate, and 80-10 wt.%, more preferably 60-30 wt.% of the aromatic polyester. A preferred type of copolymers according to the invention is formed by the group of block copolymers.

          The polyalkylene glycol may have a weight average molecular weight of about 150 to about 10000. Preferably, the polyalkylene glycol has a  
25   weight average molecular weight of 200 to 4000. The aromatic polyester preferably has a weight average molecular weight of from 200 to 9000, more preferably from 250 to 4000. The weight average molecular weight of the copolymer preferably lies between 10,000 and 300,000, more preferably between 40,000 and 120,000.



The weight average molecular weight may suitably be determined by gel permeation chromatography (GPC). This technique, which is known per se, may for instance be performed using chloroform, hexafluoro isopropanol or m-cresol as a solvent and polystyrene as external standard. Alternatively, a measure for the weight average molecular weight may be obtained by using viscometry (see NEN-EN-ISO 1628-1). This technique may for instance be performed at 25°C using chloroform as a solvent. Preferably, the intrinsic viscosity of the copolymer lies between 0.2 and 1.5 dL/g, which corresponds to a weight average molecular weight between 10,000 and 300,000. Likewise, the more preferred ranges for the weight average molecular weight measured by GPC mentioned above can also be expressed in terms of the intrinsic viscosity.

In a preferred embodiment, the polyalkylene glycol terephthalate component has units of the formula -OLO-CO-Q-CO-, wherein O represents oxygen, C represents carbon, L is a divalent organic radical remaining after removal of terminal hydroxyl groups from a poly(oxyalkylene)glycol, and Q is a divalent organic radical.

Preferred polyalkylene glycol terephthalates are chosen from the group of polyethylene glycol terephthalate, polypropylene-glycol terephthalate, and polybutylene glycol terephthalate and copolymers thereof, such as poloxamers. A highly preferred polyalkylene glycol terephthalate is polyethylene glycol terephthalate.

The terms alkylene and polyalkylene generally refer to any isomeric structure, *i.e.* propylene comprises both 1,2-propylene and 1,3-propylene, butylene comprises 1,2-butylene, 1,3-butylene, 2,3-butylene, 1,2-isobutylene, 1,3-isobutylene and 1,4-isobutylene (tetramethylene) and similarly for higher alkylene homologues. The polyalkylene glycol terephthalate component is preferably terminated with a dicarboxylic acid residue -CO-Q-CO-, if necessary to provide a coupling to the polyester component. Group Q may be an aromatic group having the same definition as R, or may be an aliphatic group such as ethylene, propylene, butylene and the like.

The polyester component preferably has units -O-E-O-CO-R-CO-, wherein O represents oxygen, C represents carbon, E is a substituted or unsubstituted alkylene or oxydialkylene radical having from 2 to 8 carbon atoms, and R is a substituted or unsubstituted divalent aromatic radical.

5 In a preferred embodiment, the polyester is chosen from the group of polyethylene terephthalate, polypropylene terephthalate, and polybutylene terephthalate. A highly preferred polyester is polybutylene terephthalate.

The preparation of the copolymer will now be explained by way of example for a polyethylene glycol terephthalate/polybutylene terephthalate  
10 copolymer. Based on this description, the skilled person will be able to prepare any desired copolymer within the above described class. An alternative manner for preparing polyalkylene glycol terephthalate/polyester copolymers is disclosed in US-A-3,908,201.

A polyethylene glycol terephthalate/polybutylene terephthalate  
15 copolymer may be synthesized from a mixture of dimethyl terephthalate, butanediol (in excess), polyethylene glycol, an antioxidant and a catalyst. The mixture is placed in a reaction vessel and heated to about 180°C, and methanol is distilled as transesterification proceeds. During the transesterification, the ester bond with methyl is replaced with an ester bond  
20 with butylene and/or the polyethylene glycol. After transesterification, the temperature is raised slowly to about 245°C, and a vacuum (finally less than 0.1 mbar) is achieved. The excess butanediol is distilled off and a prepolymer of butanediol terephthalate condenses with the polyethylene glycol to form a polyethylene/polybutylene terephthalate copolymer. A terephthalate moiety  
25 connects the polyethylene glycol units to the polybutylene terephthalate units of the copolymer and thus such a copolymer also is sometimes referred to as a polyethylene glycol terephthalate/polybutylene terephthalate copolymer (PEGT/PBT copolymer).

In principle, a coating according to the invention of the above  
30 described copolymer may be applied to any type of surface. In fact, it is one of

the great advantages of the invention that the properties of the copolymer may be adjusted over a wide range so that a good adhesion to all sorts of materials may be achieved. At the same time, the properties of the copolymer may be set such as to provide a certain desired degradability profile *in vivo*, which enables the use of the coating for controlled release of additives, such as biologically active agents. In addition, depending on the chosen composition of the copolymer, a certain swelling behaviour may be set. Swelling may serve as an additional tool to modulate release of active agents from the coating. When the coating is used on certain types of medical devices, e.g. which are subject to deformation during use in vivo, an elastic behaviour may be very useful.

Examples of materials onto the surface of which a coating according to the invention may be applied include metals and alloys, ceramics, glasses, and polymers. More specific examples of metals include stainless steel, titanium, nickel, cobalt, chrome, niobium, molybdenum, zirconium, tantalum, and combinations thereof. Further, ceramic materials, such as alumina and zirconia, glasses such as bioactive glasses made of  $\text{CaO-SiO}_2\text{-P}_2\text{O}_5$ , and calcium phosphates, such as hydroxyapatite and tricalcium phosphate, may be coated in accordance with the invention. The subject coatings can further be applied to various polymers and plastics, more preferably biocompatible or bioresorbable ones like polylactic acid or polyglycolic acid, but also polyolefines, such as (ultra high molecular weight) polyethylene and the like.

The material of which a surface is coated may be a flat, dense or a complex shaped body. It may have a porous, beaded or meshed ingrowth surface, all depending on the purpose of the body.

In a preferred embodiment, the coating is applied to a medical device, which is to be used *in vivo*. Examples of medical devices that may be coated according to the invention include, but are not limited to, catheters, fibres, non-woven fabrics, vascular grafts, porous metals for e.g. acetabulum revision, dental filling materials, materials for approximation, adhesion of tissues, materials used in osteo-synthesis (e.g. pins or bone screws), cardiac

patches, sutures, soft and hard tissue scaffolds and fillers (e.g. collagen, calcium phosphate, bioglass), stents, bone void fillers intended for the repair of bone defects, intrauterine devices, root canal fillers, drug delivery pumps, implantable infusion pumps, spacer devices, implants containing medicinal products, and scaffolds for tissue engineering.

As has been mentioned, the composition of the copolymer of which a coating according to the invention is made, may be adjusted to provide optimal properties for adhesion on various surfaces. In addition the composition may be adjusted to achieve predetermined other properties, such as swelling behaviour and biodegradability. This adjusting may be done as follows.

It envisaged that, under certain circumstances, two coatings are applied. For instance, in case the coating is to be applied to an inert surface (like a metal or metal alloy surface), a first coating of the copolymer having a relatively hydrophobic character, and a second coating of the copolymer having a different, less hydrophobic character, are applied. The first hydrophobic coating may serve to promote adhesion to the substrate, whereas the second coating may assist in or be responsible for release of a biologically active agent.

The rate of degradation of the coating may be set by the weight percentage poly(ethylene glycol) terephthalate in the copolymer. A higher relative amount of PEGT will generally result in a faster degradation.

The swelling behaviour of the coating can be influenced by the length of the poly(ethylene glycol) terephthalate segments and/or the weight percentage poly(ethylene glycol) terephthalate in the copolymer. A higher amount of PEGT, or, more important, longer PEGT segments, will generally increase the tendency of the coating to swell, as well as the extent of swelling.

The above mentioned additives that can be incorporated into the coating may vary widely in nature; in principle any type of additive may be incorporated as long as its nature or used amount does not obstruct with the coating-forming capacity of the copolymer. Depending on the envisaged application of the surface onto which the coating of the copolymer is applied,

the additive may be chosen from the group of biologically active agents. As the copolymer is biodegradable *in vivo*, and allows diffusion of molecules, the additives will be released to the surroundings of the coating in a controlled manner. This behaviour of the copolymer has previously been described in  
 5 EP-A-0 830 859. These additives may be added to the solution in amounts ranging from 0 to 50 wt.%, preferably from 1 to 20 wt.%.

The term "biologically active agent", as used herein, means an agent which provides a therapeutic or prophylactic effect. Such agents include, but are not limited to, antimicrobial agents (including antibacterial and anti-  
 10 fungal agents), anti-viral agents, anti-tumor agents, hormones immunogenic agents, growth factors, lipids, and lipopolysaccharides.

Biologically active agents which may be incorporated include, but are not limited to, non-peptide, non-protein small-sized drugs. They have a molecular weight which in general is less than 1500, and in particular less  
 15 than 500. A second important group of biologically active agents are biologically active peptides and proteins.

Examples of non-peptide, non-protein small-sized drugs which may be incorporated include, but are not limited to, the following:

1. Anti-tumor agents: altretamin, fluorouracil, amsacrin, hydroxycarbamide,  
 20 asparaginase, ifosfamid, bleomycin, lomustin, busulfan, melphalan, chlorambucil, mercaptopurin, chlormethin, methotrexate, cisplatin, mitomycin, cyclophosphamide, procarbazine, cytarabin, teniposid, dacarbazine, thiotepa, dactinomycin, tioguanin, daunorubicin, treosulphan, doxorubicin, tiophosphamide, estramucin, vinblastine, etoglucide, vincristine, etoposid,  
 25 vindesine.

2. Antimicrobial agents

### 2.1 Antibiotics

*Penicillins*: ampicillin, nafcillin, amoxicillin, oxacillin, azlocillin,  
 30 penicillin G, carbenicillin, penicillin V, dicloxacillin, phenethicillin,

floxacillin, piperacillin, mecillinam, sulbenicillin, methicillin, ticarcillin, mezlocillin

*Cephalosporins*: cefaclor, cephalothin, cefadroxil, cephapirin, cefamandole, cephradine, cefatrizine, cefsulodine, cefazolin, ceftazidim, ceforanide, ceftriaxon, cefoxitin, cefuroxime, cephacetrile, latamoxef, cephalixin

*Aminoglycosides*: amikacin, neomycin, dibekacyn, kanamycin, gentamycin, netilmycin, kanamycin, tobramycin

*Macrolides*: amphotericin B, novobiocin, bacitracin, nystatin, clindamycin, polymyxins, colistin, rovamycin, erythromycin, spectinomycin, lincomycin, vancomycin

*Tetracyclines*: chlortetracycline, oxytetracycline, demeclocycline, rolitetracycline, doxycycline, tetracycline, minocycline

*Other antibiotics*: chloramphenicol, rifamycin, rifampicin, thiamphenicol

## 2.2 Chemotherapeutic agents

*Sulfonamides*: sulfadiazine, sulfamethizol, sulfadimethoxin, sulfamethoxazole, sulfadimidin, sulfamethoxypyridazine, sulfafurazole, sulfaphenazol, sulfalene, sulfisomidin, sulfamerazine, sulfisoxazole, trimethoprim with sulfamethoxazole or sulfametrole

*Urinary tract antiseptics*: methanamine, quinolones (norfloxacin, cinoxacin), nalidixic acid, nitro-compounds (nitrofurantoin, nifurtoinol), oxolinic acid

*Anaerobic infections*: metronidazole

3. Drugs for tuberculosis: aminosalicylic acid, isoniazide, cycloserine, rifampicine, ethambutol, tiocarlide, ethionamide, viomycin

4. Drugs for leprosy: amithiozone, rifampicine, clofazimine, sodium sulfoxone, diaminodiphenylsulfone (DDS, dapsone)

5. Antifungal agents: amphotericin B, ketoconazole, clotrimazole, miconazole, econazole, natamycin, flucytosine, nystatine, griseofulvin

6. Antiviral agents: aciclovir, idoxuridine, amantidine, methisazone, cytarabine, vidarabine, ganciclovir
7. Chemotherapy of amebiasis: chloroquine, iodoquinol, clioquinol, metronidazole, dehydroemetine, paromomycin, diloxanide, furoatetinidazole, emetine
8. Anti-malarial agents: chloroquine, pyrimethamine, hydroxychloroquine, quinine, mefloquine, sulfadoxine/pyrimethamine, pentamidine, sodium suramin, primaquine, trimethoprim, proguanil
9. Anti-helminthiasis agents: antimony potassium tartrate, niridazole, antimony sodium dimercaptosuccinate, oxamniquine, bephenium, piperazine, dichlorophen, praziquantel, diethylcarbamazine, pyrantel pamoate, hycanthone, pyrivium pamoate, levamisole, stibophen, mebendazole, tetramisole, metrifonate, thiobendazole, niclosamide
10. Anti-inflammatory agents: acetylsalicyclic acid, mefenamic acid, aclofenac, naproxen, azopropanone, niflumic acid, benzydamine, oxyphenbutazone, diclofenac, piroxicam, fenoprofen, pirprofen, flurbiprofen, sodium salicylate, ibuprofensulindac, indomethacin, tiaprofenic acid, ketoprofen, tolmetin
11. Anti-gout agents: colchicine, allopurinol
12. Centrally acting (opoid) analgesics: alfentanil, methadone, bezitramide, morphine, buprenorfine, nicomorphine, butorfanol, pentazocine, codeine, pethidine, dextromoramide, piritranide, dextropropoxyphene, sufentanil, fentanyl
13. Local anesthetics: articaine, mepivacaine, bupivacaine, prilocaine, etidocaine, procaine, lidocaine, tetracaine
14. Drugs for Parkinson's disease: amantidine, diphenhydramine, apomorphine, ethopropazine, benztropine mesylate, lergotril, biperiden, levodopa, bromocriptine, lisuride, carbidopa, metixen, chlorphenoxamine, orphenadrine, cycrimine, procyclidine, dexetimide, trihexyphenidyl

15. Centrally active muscle relaxants: baclofen, carisoprodol, chlormezanone, chlorzoxazone, cyclobenzaprine, dantrolene, diazepam, febarbamate, mefenoxalone, mephenesin, metoxalone, methocarbamol, tolperisone
16. Hormones and hormone antagonistics

5

### 16.1 Corticosteroids

16.1.1 *Mineralocorticosteroids*: cortisol, desoxycorticosterone, flurohydrocortisone

10

16.1.2 *Glucocorticosteroids*: beclomethasone, betamethasone, cortisone, dexamethasone, fluocinolone, fluocinonide, fluocortolone, fluorometholone, fluprednisolone, flurandrenolide, halcinonide, hydrocortisone, medrysone, methylprednisolone, paramethasone, prednisolone, prednisone, triamcinolone (acetone)

15

### 16.2 Androgens

16.2.1 *Androgenic steroids used in therapy*: danazole, fluoxymesterone, mesterolone, methyltestosterone, testosterone and salts thereof

20

16.2.2 *Anabolic steroids used in therapy*: calusterone, nandrolone and salts thereof, dromostanolone, oxandrolone, ethylestrenol, oxymetholone, methandriol, stanozolol methandrostenolone, testolactone

16.2.3 *Antiandrogens*: cyproterone acetate

25

### 16.3 Estrogens

16.3.1 *Estrogenic steroids used in therapy*: diethylstilbestrol, estradiol, estriol, ethinylestradiol, mestranol, quinestrol



16.3.2 *Anti-estrogens*: chlorotrianisene, clomiphene, ethamoxytriphetol, nafoxidine, tamoxifen

5 16.4 *Progestins*: allylestrenol, desogestrel, dimethisterone, dydrogesterone, ethinylestrenol, ethisterone, ethynadiol diacetate, etynodiol, hydroxyprogesterone, levonorgestrel, lynestrenol, medroxyprogesterone, megestrol acetate, norethindrone, norethisterone, norethynodrel, norgestrel, progesterone

## 10 17. Thyroid drugs

17.1 Thyroid drugs used in therapy: levothyronine, liothyronine

17.2 *Anti-thyroid drugs used in therapy*: carbimazole, methimazole, methylthiouracil, propylthiouracil

15

When a non-peptide, non-protein, small-sized drug, such as those described above, is to be incorporated, the polyalkylene glycol terephthalate component of the copolymer preferably has a molecular weight of from about 200 to 400. Also, the polyalkylene glycol terephthalate component is present in the copolymer in an amount of from 20 wt.% to 90 wt.% of the weight of the copolymer, preferably from about 40 wt.% to about 70 wt.% of the weight of the copolymer. In general, the aromatic polyester is present in the copolymer in an amount of from 10 wt.% to 80 wt.% of the copolymer, preferably in an amount of from about 30 wt.% to about 60 wt.% of the copolymer.

25

When a hydrophobic small-sized drug, such as, for example, a steroid hormone is incorporated, preferably at least one hydrophobic antioxidant is present. Hydrophobic antioxidants which may be employed include, but are not limited to, tocopherols, such as  $\alpha$ -tocopherol,  $\beta$ -tocopherol,  $\gamma$ -tocopherol,  $\delta$ -tocopherol,  $\epsilon$ -tocopherol,  $\zeta_1$ -tocopherol,  $\zeta_2$ -tocopherol, and  $\eta$ -tocopherol; and 1-ascorbic acid 6-palmitate. Such hydrophobic antioxidants

30

retard the degradation of the copolymer and retard the release of the biologically active agent. Thus, the use of a hydrophobic or lipophilic antioxidant is applicable particularly to the formation of matrices which include drugs which tend to be released quickly from the coating, such as, for example, small drug molecules having a molecular weight less than 500. The at least one hydrophobic antioxidant may be present in the coating in an amount of from about 0.1 wt.% to about 10 wt.% of the total weight of the matrix, preferably from about 0.5 wt.% to about 2 wt.%.

When the coating includes a hydrophilic small-sized drug, such as an aminoglycoside, it may also include, in addition to the hydrophobic antioxidant, a hydrophobic molecule such as cholesterol, ergosterol, lithocholic acid, cholic acid, dinosterol, betuline, or oleanolic acid, which may be employed in order to retard the release rate of the agent from the copolymer coating. Such hydrophobic molecules prevent water penetration into the coating, but do not compromise the degradability of the coating. In addition, such molecules have melting points from 150°C to 200°C or decreases the coating diffusion coefficient for the biologically active agent, such as small drug molecule, to be released. Thus, such hydrophobic molecules provide for a more sustained release of a biologically active agent from the coating. The at least one hydrophobic molecule may be present in the coating in an amount of from about 0.1 wt.% to about 20 wt.%, preferably from 1.0 wt.% to 5.0 wt.%.

If it is desired to increase the hydrophilicity of the polymer, and thereby increase the degradation rate and drug releasing rate of the copolymer, the copolymer may be modified by partially replacing the aromatic moiety with an aliphatic moiety such as succinate and/or by replacing partially the alkylene with dioxyethylene. For example, terephthalate can be replaced by succinate in an amount of from about 0.1 mole% to about 20 mole%, preferably from about 0.1 mole% to about 5 mole%, by partially replacing dimethyl terephthalate as a starting component with dimethyl succinate. As another example, butylene is replaced with oxydiethylene in an amount of

from about 0.1 mole% to about 20 mole%, preferably from about 0.5 mole% to about 2 mole%, by replacing 1,4-butanediol with dimethyleneglycol as a starting component.

5 Examples of peptides or proteins which may advantageously be contained in the coating include, but are not limited to, immunogenic peptides or immunogenic proteins, which include, but are not limited to, the following:

*Growth factors:* bone morphogenetic proteins, transforming growth factors, fibroblast growth factors, epidermal growth factors, etc.

10 *Toxins:* diphtheria toxin, tetanus toxin

*Viral surface antigens or parts of viruses:* adenoviruses, Epstein-Barr Virus, Hepatitis A Virus, Hepatitis B Virus, Herpes viruses, HIV-1, HIV-2, HTLV-III, Influenza viruses, Japanese encephalitis virus, Measles virus, Papilloma viruses, Paramyxoviruses, Polio Virus, Rabies, Virus, Rubella Virus, Vaccinia (Smallpox) viruses, Yellow Fever Virus

15 *Bacterial surface antigens or parts of bacteria:* Bordetella pertussis, Helicobacter pylori, Clostridium tetani, Corynebacterium diphtheria, Escherichia coli, Haemophilus influenza, Klebsiella species, Legionella pneumophila, Mycobacterium bovis, Mycobacterium leprae, Mycobacterium tuberculosis, Neisseria gonorrhoeae, Neisseria meningitidis, Proteus species, Pseudomonas aeruginosa, Salmonella species, Shigella species, Staphylococcus aureus, Streptococcus pyogenes, Vibrio cholera, Yersinia pestis

*Surface antigens of parasites causing disease or portions of parasites:*

25 Plasmodium vivax - malaria, Plasmodium falciparum - malaria, Plasmodium ovale - malaria, Plasmodium malariae - malaria, Leishmania tropica - leishmaniasis, Leishmania donovani, leishmaniasis, Leishmania branziliensis - leishmaniasis, Trypanosoma rhodescense - sleeping sickness, Trypanosoma gambiense - sleeping sickness, Trypanosoma cruzi - Chagas' disease, Schistosoma mansoni -

30

schistosomiasis, *Schistosomoma haematobium* - schistomiasis,  
*Schistosoma japonicum* - shichtomiasis, *Trichinella spiralis* - trichinosis,  
*Strongyloides duodenale* - hookworm, *Ancylostoma duodenale* -  
hookworm, *Necator americanus* - hookworm, *Wucheria bancrofti* -  
5      *filariasis*, *Brugia malaya* - *filariasis*, *Loa loa* - *filariasis*, *Dipetalonema*  
*perstans* - *filariasis*, *Dracuncula medinensis* - *filariasis*, *Onchocerca*  
*volvulus* - *filariasis*  
*Immunoglobulins*: IgG, IgA, IgM, Antirabies immunoglobulin,  
Antivaccinia immunoglobulin *Antitoxins*: Botulinum antitoxin,  
10      diphtheria antitoxin, gas gangrene antitoxin, tetanus antitoxin.

Other peptides or proteins which may be encapsulated include, but  
are not limited to, antigens which elicit an immune response against Foot and  
Mouth Disease, hormones and growth factors such as follicle stimulating  
15      hormone, prolactin, angiogenin, epidermal growth factor, calcitonin,  
erythropoietin, thyrotropic releasing hormone, insulin, growth hormones,  
insulin-like growth factors 1 and 2, skeletal growth factor, human chorionic  
gonadotropin, luteinizing hormone, nerve growth factor, adrenocorticotrophic  
hormone (ACTH), luteinizing hormone releasing hormone (LHRH),  
20      parathyroid hormone (PTH), thyrotropin releasing hormone (TRH),  
vasopressin, cholecystokinin, and corticotropin releasing hormone; cytokines,  
such as interferons, interleukins, colony stimulating factors, and tumor  
necrosis factors: fibrinolytic enzymes, such as urokinase, kidney plasminogen  
activator; and clotting factors, such as Protein C, Factor VIII, Factor IX, Factor  
25      VII and Antithrombin III. Examples of other proteins or peptides which may  
be encapsulated include, but are not limited to, albumin, atrial natriuretic  
factor, renin, superoxide dismutase,  $\alpha_1$ -antitrypsin, lung surfactant proteins,  
bacitracin, bestatin, cyclosporine, delta sleep-inducing peptide (DSIP),  
endorphins, glucagon, gramicidin, melanocyte inhibiting factors, neurotensin,  
30      oxytocin, somostatin, terprotide, serum thymide factor, thymosin, DDAVP,

dermorphin, Met-enkephalin, peptidoglycan, satietin, thymopentin, fibrin degradation product, des-enkephalin- $\alpha$ -endorphin, gonadotropin releasing hormone, leuprolide,  $\alpha$ -MSH, and metkephamid. It is to be understood, however, that the scope of the present invention is not limited to any specific peptides or proteins.

Before applying the coating, the surface to which it is to be applied is preferably cleaned or treated to remove any contaminants and to promote good adhesion of the coating. Various methods for cleaning may be employed. The metallic implants may be rinsed with a degreaser, *i.e.* acetone, alkyl alcohols, etc. and then thoroughly rinsed with pure water.

In order to improve coating adhesion, various surface treatments may be applied to metal implants. Mechanical surface treatments, such as sand-blasting, scoring, polishing and grinding can increase surface roughness of the implants and improve the bonding strength between the coatings and metal substrate. For similar purposes, chemical surface treatments may be also applied to metal substrates prior to coating. Among others chemical treatments available for metals, acid etchings will be preferred by treating implantable devices with strong mineral acids, such as hydrofluoric, hydrochloric, sulfuric, nitric and perchloric acids. It may also useful to treat the metal devices with oxidising agents such as nitric acid, peroxyhalogen acids, hydroxyperoxides, or hydrogen peroxide to form a fresh metal oxide layer. After the mechanical or chemical treatment, it is necessary to rinse the implants with pure water under ultrasound for removal of surface contaminants.

A coating according to the invention may be applied to a surface by methods known to those skilled in the art, like by brushing, spraying, wiping, dipping, extruding or injecting. The latter three methods are preferred when porous structures or fibrous meshes are to be coated. Use of these methods allows penetration of the copolymer of which the coating is formed inside the

pores of the devices and a (uniform) coating of the total surface area. Brushing and spraying are preferred in case of non-porous devices.

If desired, organic solvents may be used to dissolve the copolymer. Suitable solvents are chloroform, dichloromethane, N-methyl-2-pyrrolidone, dimethyl sulfoxide, acetone, hexafluoroisopropanol and the like. The selection of a suitable solvent will be dependent on the composition of the chosen copolymer. Alternatively, heat may be applied to process a copolymer of which a coating is to be formed.

A biologically active agent may be incorporated into the coating by dissolving it in the copolymer solution of which the coating is formed. Hence, a homogeneous solution is formed or a suspension is formed by dispersion. Alternatively, a solution of a biologically active agent may be mixed with the copolymer solution to form a homogeneous mixture, or an emulsion. Also, a biologically agent can be incorporated by physically mixing with the copolymer, for example by extrusion. Since in the latter case heat is applied, care must be taken not to harm the stability and/or activity of the biologically active agent.

If it is desired that a porous coating is formed, a pore-forming agent can be included in the solution or suspension of the copolymer from which the coating is formed. Pore-forming agents may include organic solvents, water, salts (sodium chloride, sodium citrate, and the like), sugars and water-soluble synthetic polymers. Using such pore-forming agents, pores can be created by leaching-out of the agent, or by phase separation.

The thickness of the coatings of this invention may range from a few microns up to any desired thickness (up to a few hundred microns). The thickness of the coating may be adjusted by the viscosity of the copolymer solution that is used to prepare the coating. The viscosity of the copolymer solution may be adjusted by parameters like the molecular weight of the copolymer, the copolymer concentration in the solution, the selected solvent,

the temperature, etc. In case of spraying or brushing, spraying time and flow rate may also influence the thickness of the coating.

The invention will be further elucidated by the following, non-restrictive example.


5

#### Example

A porous scaffold was produced as described in example 1 of European patent application 01200328.1, the contents of which are incorporated herein by reference, from a copolymer of polyethylene glycol (PEG, MW = 300 g/mole) and polybutylene terephthalate (PBT), wherein the weight percentage PBT was 55 %. The porosity of the scaffold was approximately 77 v/v%. About 400 mg of the scaffold to be coated was placed on a grid that was connected to a vacuum pump (see figure 1 for a schematic representation).

15 The coating emulsion was prepared by mixing a protein solution (1.0 ml, 50 mg lysozyme per ml phosphate buffered saline (PBS), pH 7.4) with a polymer solution (6 ml chloroform, 1g copolymer of polyethylene glycol (PEG, MW = 1000 g/mole) and polybutylene terephthalate (PBT), wherein the weight percentage PBT was 30 %.) using ultra-turrax mixing (30 s at 19 krpm, Ika Labortechnik T25). The resulting water-in-oil emulsion was poured on top of the scaffold, and a vacuum of 300 Torr was applied for 5 minutes. Thereafter, the scaffolds were dried overnight under vacuum at room temperature.

25 To evaluate the release of lysozyme from the coated scaffolds, pieces of approximately 75 mg were incubated in 1 ml PBS (pH 7.4). Vials were continuously shaken at 37°C and samples were taken at various time points. The protein concentration in the buffer solution was determined using a standard Coomassie Blue assay (Pierce). In figure 2, the release of lysozyme from the coated scaffolds is presented.





Claims

(45)

1. A coating for a medical device comprising a copolymer of a polyalkylene glycol terephthalate and an aromatic polyester.
2. A coating according to claim 1, wherein the polyalkylene glycol is chosen from the group of polyethylene glycol terephthalate, polypropylene glycol terephthalate, and polybutylene glycol terephthalate.
3. A coating according to claim 2, wherein the polyalkylene glycol is polyethylene glycol terephthalate.
4. A coating according to any of the preceding claims, wherein the polyester is chosen from the group of polyethylene terephthalate, polypropylene terephthalate, and polybutylene terephthalate.
5. A coating according to claim 4, wherein the polyester is polybutylene terephthalate.
6. A coating according to any of the preceding claims, wherein the copolymer comprises 20-90 wt.%, preferably 40-70 wt.%, based on the weight of the copolymer, of the polyalkylene glycol.
7. A coating according to any of the preceding claims, wherein the weight average molecular weight of the polyalkylene glycol is from about 150 to about 4000, preferably from about 200 to about 1500.
8. A coating according to any of the preceding claims, wherein the weight average molecular weight of the copolymer lies between about 10,000 and about 300,000, preferably between about 40,000 and about 120,000.
9. A coating according to any of the preceding claims further comprising an additive.
10. A coating according to claim 9, wherein the additive is a biologically active agent chosen from the group of antimicrobial agents, such as antibacterial and anti-fungal agents, anti-viral agents, anti-tumor agents, immunogenic agents, lipids, lipopolysaccharides, hormones and growth factors.

11. A coating according to claim 9, wherein the additive is a biologically active agent is chosen from the group of peptides, oligopeptides, polypeptides and proteins.
12. A coating according to any of the preceding claims, applied to a surface  
5 chosen from the group of metals, metal alloys, ceramics, glasses and polymeric materials.
13. A coating according to claim 12, wherein the surface is a surface of a medical device chosen from the group of catheters, stents, fibres, non-woven fabrics, vascular grafts, porous metals for e.g. acetabulum revision, and porous  
10 scaffolds for tissue engineering.
14. A coating according to any of the preceding claim, which is porous.
15. A method for applying a coating according to any of the preceding claims to a surface, comprising brushing, spraying, wiping, dipping, extruding or injecting.
- 15 16. A method according to claim 15, wherein the surface is cleaned and/or subjected to a mechanical treatment prior to application of the coating.
17. A method according to claim 15 or 16, wherein the coating is applied from a solution or suspension of the copolymer.
18. A method according to claim 17, wherein a biologically active agent is  
20 included in the solution or suspension.
19. A method according to claim 17 or 18, wherein a pore-forming agent is included in the solution or suspension.
20. A medical device comprising a coating according to any of the claims 1-13.
- 25 21. A medical device according to claim 20 chosen from the group of catheters, fibres, non-woven fabrics, vascular grafts, porous metals for e.g. acetabulum revision, dental filling materials, materials for approximation, adhesion of tissues, materials used in osteo-synthesis (e.g. pins or bone screws), cardiac patches, sutures, soft and hard tissue scaffolds and fillers (e.g.  
30 collagen, calcium phosphate, bioglass), stents, bone void fillers intended for the

repair of bone defects, intrauterine devices, root canal fillers, drug delivery pumps, implantable infusion pumps, spacer devices, implants containing medicinal products, and scaffolds for tissue engineering.



Title: Coating for medical devices

Abstract

The invention relates to a coating for medical devices. The coating comprises a specific copolymer of which the composition may be adjusted such as to achieve an excellent adhesion to a wide range of surfaces. The coating may further comprise an additive, such as a biologically active agent, which may be released *in vivo* in a controlled manner, as the degradability of the coating may also be adjusted to a predetermined rate. The invention further relates to a process for applying the coating to a surface and to a medical device comprising the coating.






Figure 1: Principle of coating of a porous scaffold using an protein containing emulsion.




Figure 2: Release of lysozyme from coated scaffolds



KONINKRIJK DER



NEDERLANDEN

Bureau voor de Industriële Eigendom



This is to declare that in the Netherlands on April 2, 2002 under No. PCT/NL02/00212,  
in the name of:

**ISOTIS N.V.**

in Bilthoven, The Netherlands and

**Jerome SOHIER**

in Zeist, The Netherlands and

**Mattijs Jeroen BEZEMER**

in Utrecht, The Netherlands and

an international patent application was filed for:

"Coating for medical devices",

that a right of priority was claimed based on patent application 01201259.7 filed on April 04,  
2001 in Europe, and that the documents attached hereto correspond with the originally filed  
documents.

Rijswijk, February 2, 2004.

In the name of the president of the Netherlands Industrial Property Office

A handwritten signature in black ink, appearing to be 'M.M. Enhus'.

Mw. M.M. Enhus

4

11

Title: Coating for medical devices

The invention relates to a coating for medical devices. The invention further relates to a process for applying a coating to a surface, *e.g.* a surface of a medical device, and to a medical device comprising said coating.

Great effort has been put into studies of coatings for medical devices.

5 Materials used for the manufacture of medical devices are not always chosen from a biocompatibility point of view as often other considerations, *e.g.* with respect to strength or tensile and stretching properties, prevail.

Coatings for medical devices are, however, not only interesting for enhancing the biocompatibility of a medical device. They also provide a  
10 possibility to provide a controlled release of biologically active agents, in which case it is necessary that the coating is also biodegradable.

Problems encountered in the design of coatings for medical devices are many. One of the bigger problems concerns the adhesion of the coating to the material of which the medical device is made. As many different materials,  
15 varying from metals to ceramics and polymeric materials, are used for the manufacture of medical devices, it is important that a good coating adheres sufficiently to all sorts of materials. This is, however, often not the case.

Another problem concerns the conditions a medical device is subjected to during use. Certain medical devices, such as catheters, are for  
20 instance subjected to deformation *in vivo*. When the device expands, it is important that the coating is capable of undergoing the same deformation without breaking or coming loose. This would lead to exposure of the surface of the material of the medical device to the surrounding tissue *in vivo*. In the worst case, parts of the coating might detach from the device completely.

25 Accordingly, there is a need for a coating material for medical devices which may be used universally for different sorts of medical devices of different materials.

The invention provides a coating that fulfils this need. A specific copolymer has been found of which the properties may be adjusted to the needs




and requirements of application on a specific medical device of a specific material. Accordingly, the invention relates to a coating for a medical device comprising a copolymer of a polyalkylene glycol terephthalate and an aromatic polyester.

5           A coating according to the invention may be applied to a wide range of materials. It is one of the great advantages of the invention that the composition of the copolymer may be adjusted such as to achieve a good adhesion to nearly any type of material. The nature and molecular weights of the monomers of the copolymer, as well as the ratio of the two monomers and  
10   the molecular weight of the copolymer itself, provide a multitude of variations that can be used to achieve an optimum property profile of a coating. These parameters do not only serve to adjust the adhesion of the coating. Other properties can be optimised as well. Examples of such properties include the degradability and swelling behaviour of the coating and mechanical properties,  
15   like elasticity and tensile strength. Other properties and advantages will become clear from the following, more detailed description of the invention.

          A coating according to the invention comprises a copolymer of a polyalkylene glycol terephthalate and an aromatic polyester. Preferably, the copolymer comprises 20-90 wt.%, more preferably 40-70 wt.% of the  
20   polyalkylene glycol terephthalate, and 80-10 wt.%, more preferably 60-30 wt.% of the aromatic polyester. A preferred type of copolymers according to the invention is formed by the group of block copolymers.

          The polyalkylene glycol may have a weight average molecular weight of about 150 to about 10000. Preferably, the polyalkylene glycol has a  
25   weight average molecular weight of 200 to 4000. The aromatic polyester preferably has a weight average molecular weight of from 200 to 9000, more preferably from 250 to 4000. The weight average molecular weight of the copolymer preferably lies between 10,000 and 300,000, more preferably between 40,000 and 120,000.



The weight average molecular weight may suitably be determined by gel permeation chromatography (GPC). This technique, which is known per se, may for instance be performed using chloroform, hexafluoro isopropanol or m-cresol as a solvent and polystyrene as external standard. Alternatively, a  
5 measure for the weight average molecular weight may be obtained by using viscometry (see NEN-EN-ISO 1628-1). This technique may for instance be performed at 25°C using chloroform as a solvent. Preferably, the intrinsic viscosity of the copolymer lies between 0.2 and 1.5 dL/g, which corresponds to a weight average molecular weight between 10,000 and 300,000. Likewise, the  
10 more preferred ranges for the weight average molecular weight measured by GPC mentioned above can also be expressed in terms of the intrinsic viscosity.

In a preferred embodiment, the polyalkylene glycol terephthalate component has units of the formula -OLO-CO-Q-CO-, wherein O represents oxygen, C represents carbon, L is a divalent organic radical remaining after  
15 removal of terminal hydroxyl groups from a poly(oxyalkylene)glycol, and Q is a divalent organic radical.

Preferred polyalkylene glycol terephthalates are chosen from the group of polyethylene glycol terephthalate, polypropylene glycol terephthalate, and polybutylene glycol terephthalate and copolymers thereof, such as  
20 poloxamers. A highly preferred polyalkylene glycol terephthalate is polyethylene glycol terephthalate.

The terms alkylene and polyalkylene generally refer to any isomeric structure, *i.e.* propylene comprises both 1,2-propylene and 1,3-propylene, butylene comprises 1,2-butylene, 1,3-butylene, 2,3-butylene, 1,2-isobutylene,  
25 1,3-isobutylene and 1,4-isobutylene (tetramethylene) and similarly for higher alkylene homologues. The polyalkylene glycol terephthalate component is preferably terminated with a dicarboxylic acid residue -CO-Q-CO-, if necessary to provide a coupling to the polyester component. Group Q may be an aromatic group having the same definition as R, or may be an aliphatic group such as  
30 ethylene, propylene, butylene and the like.





The polyester component preferably has units -O-E-O-CO-R-CO-, wherein O represents oxygen, C represents carbon, E is a substituted or unsubstituted alkylene or oxydialkylene radical having from 2 to 8 carbon atoms, and R is a substituted or unsubstituted divalent aromatic radical.

5 In a preferred embodiment, the polyester is chosen from the group of polyethylene terephthalate, polypropylene terephthalate, and polybutylene terephthalate. A highly preferred polyester is polybutylene terephthalate.

The preparation of the copolymer will now be explained by way of example for a polyethylene glycol terephthalate/polybutylene terephthalate  
10 copolymer. Based on this description, the skilled person will be able to prepare any desired copolymer within the above described class. An alternative manner for preparing polyalkylene glycol terephthalate/polyester copolymers is disclosed in US-A-3,908,201.

A polyethylene glycol terephthalate/polybutylene terephthalate  
15 copolymer may be synthesized from a mixture of dimethyl terephthalate, butanediol (in excess), polyethylene glycol, an antioxidant and a catalyst. The mixture is placed in a reaction vessel and heated to about 180°C, and methanol is distilled as transesterification proceeds. During the transesterification, the ester bond with methyl is replaced with an ester bond  
20 with butylene and/or the polyethylene glycol. After transesterification, the temperature is raised slowly to about 245°C, and a vacuum (finally less than 0.1 mbar) is achieved. The excess butanediol is distilled off and a prepolymer of butanediol terephthalate condenses with the polyethylene glycol to form a polyethylene/polybutylene terephthalate copolymer. A terephthalate moiety  
25 connects the polyethylene glycol units to the polybutylene terephthalate units of the copolymer and thus such a copolymer also is sometimes referred to as a polyethylene glycol terephthalate/polybutylene terephthalate copolymer (PEGT/PBT copolymer).

In principle, a coating according to the invention of the above  
30 described copolymer may be applied to any type of surface. In fact, it is one of



the great advantages of the invention that the properties of the copolymer may be adjusted over a wide range so that a good adhesion to all sorts of materials may be achieved. At the same time, the properties of the copolymer may be set such as to provide a certain desired degradability profile *in vivo*, which enables  
5 the use of the coating for controlled release of additives, such as biologically active agents. In addition, depending on the chosen composition of the copolymer, a certain swelling behaviour may be set. Swelling may serve as an additional tool to modulate release of active agents from the coating. When the coating is used on certain types of medical devices, e.g. which are subject to  
10 deformation during use *in vivo*, an elastic behaviour may be very useful.

Examples of materials onto the surface of which a coating according to the invention may be applied include metals and alloys, ceramics, glasses, and polymers. More specific examples of metals include stainless steel, titanium, nickel, cobalt, chrome, niobium, molybdenum, zirconium, tantalum,  
15 and combinations thereof. Further, ceramic materials, such as alumina and zirconia, glasses such as bioactive glasses made of  $\text{CaO-SiO}_2\text{-P}_2\text{O}_5$ , and calcium phosphates, such as hydroxyapatite and tricalcium phosphate, may be coated in accordance with the invention. The subject coatings can further be applied to various polymers and plastics, more preferably biocompatible or  
20 bioresorbable ones like polylactic acid or polyglycolic acid, but also polyolefines, such as (ultra high molecular weight) polyethylene and the like.

The material of which a surface is coated may be a flat, dense or a complex shaped body. It may have a porous, beaded or meshed ingrowth surface, all depending on the purpose of the body.

25 In a preferred embodiment, the coating is applied to a medical device, which is to be used *in vivo*. Examples of medical devices that may be coated according to the invention include, but are not limited to, catheters, fibres, non-woven fabrics, vascular grafts, porous metals for e.g. acetabulum revision, dental filling materials, materials for approximation, adhesion of  
30 tissues, materials used in osteo-synthesis (e.g. pins or bone screws), cardiac



patches, sutures, soft and hard tissue scaffolds and fillers (e.g. collagen, calcium phosphate, bioglass), stents, bone void fillers intended for the repair of bone defects, intrauterine devices, root canal fillers, drug delivery pumps, implantable infusion pumps, spacer devices, implants containing medicinal products, and scaffolds for tissue engineering.

As has been mentioned, the composition of the copolymer of which a coating according to the invention is made, may be adjusted to provide optimal properties for adhesion on various surfaces. In addition the composition may be adjusted to achieve predetermined other properties, such as swelling behaviour and biodegradability. This adjusting may be done as follows.

It envisaged that, under certain circumstances, two coatings are applied. For instance, in case the coating is to be applied to an inert surface (like a metal or metal alloy surface), a first coating of the copolymer having a relatively hydrophobic character, and a second coating of the copolymer having a different, less hydrophobic character, are applied. The first hydrophobic coating may serve to promote adhesion to the substrate, whereas the second coating may assist in or be responsible for release of a biologically active agent.

The rate of degradation of the coating may be set by the weight percentage poly(ethylene glycol) terephthalate in the copolymer. A higher relative amount of PEGT will generally result in a faster degradation.

The swelling behaviour of the coating can be influenced by the length of the poly(ethylene glycol) terephthalate segments and/or the weight percentage poly(ethylene glycol) terephthalate in the copolymer. A higher amount of PEGT, or, more important, longer PEGT segments, will generally increase the tendency of the coating to swell, as well as the extent of swelling.

The above mentioned additives that can be incorporated into the coating may vary widely in nature; in principle any type of additive may be incorporated as long as its nature or used amount does not obstruct with the coating-forming capacity of the copolymer. Depending on the envisaged application of the surface onto which the coating of the copolymer is applied,



the additive may be chosen from the group of biologically active agents. As the copolymer is biodegradable *in vivo*, and allows diffusion of molecules, the additives will be released to the surroundings of the coating in a controlled manner. This behaviour of the copolymer has previously been described in  
5 EP-A-0 830 859. These additives may be added to the solution in amounts ranging from 0 to 50 wt.%, preferably from 1 to 20 wt.%.

The term "biologically active agent", as used herein, means an agent which provides a therapeutic or prophylactic effect. Such agents include, but are not limited to, antimicrobial agents (including antibacterial and anti-  
10 fungal agents), anti-viral agents, anti-tumor agents, hormones immunogenic agents, growth factors, lipids, and lipopolysaccharides.

Biologically active agents which may be incorporated include, but are not limited to, non-peptide, non-protein small-sized drugs. They have a molecular weight which in general is less than 1500, and in particular less  
15 than 500. A second important group of biologically active agents are biologically active peptides and proteins.

Examples of non-peptide, non-protein small-sized drugs which may be incorporated include, but are not limited to, the following:

1. Anti-tumor agents: altretamin, fluorouracil, amsacrin, hydroxycarbamide,  
20 asparaginase, ifosfamid, bleomycin, lomustin, busulfan, melphalan, chlorambucil, mercaptopurin, chlormethin, methotrexate, cisplatin, mitomycin, cyclophosphamide, procarbazine, cytarabin, teniposid, dacarbazine, thiotepa, dactinomycin, tioguanin, daunorubicin, treosulphan, doxorubicin, tiophosphamide, estramucin, vinblastine, etoglucide, vincristine, etoposid,  
25 vindesine.

2. Antimicrobial agents

### 2.1 Antibiotics

*Penicillins*: ampicillin, nafcillin, amoxicillin, oxacillin, azlocillin,  
30 penicillin G, carbenicillin, penicillin V, dicloxacillin, phenethicillin,





floxacillin, piperacillin, mecillinam, sulbenicillin, methicillin, ticarcillin, mezlocillin

*Cephalosporins*: cefaclor, cephalothin, cefadroxil, cephapirin, cefamandole, cephadrine, cefatrizine, cefsulodine, cefazolin, ceftazidim, ceforanide, ceftriaxon, cefoxitin, cefuroxime, cephacetrile, latamoxef, cephalixin

*Aminoglycosides*: amikacin, neomycin, dibekacyn, kanamycin, gentamycin, netilmycin, kanamycin, tobramycin

*Macrolides*: amphotericin B, novobiocin, bacitracin, nystatin, clindamycin, polymyxins, colistin, rovamycin, erythromycin, spectinomycin, lincomycin, vancomycin

*Tetracyclines*: chlortetracycline, oxytetracycline, demeclocycline, rolitetracycline, doxycycline, tetracycline, minocycline

*Other antibiotics*: chloramphenicol, rifamycin, rifampicin, thiamphenicol

## 2.2 Chemotherapeutic agents

*Sulfonamides*: sulfadiazine, sulfamethizol, sulfadimethoxin, sulfamethoxazole, sulfadimidin, sulfamethoxypyridazine, sulfafurazole, sulfaphenazol, sulfalene, sulfisomidin, sulfamerazine, sulfisoxazole, trimethoprim with sulfamethoxazole or sulfametrole

*Urinary tract antiseptics*: methanamine, quinolones(norfloxacin, cinoxacin), nalidixic acid, nitro-compounds (nitrofurantoin, nifurtoinol), oxolinic acid

*Anaerobic infections*: metronidazole

3. Drugs for tuberculosis: aminosalicylic acid, isoniazide, cycloserine, rifampicine, ethambutol, tiocarlide, ethionamide, viomycin

4. Drugs for leprosy: amithiozone, rifampicine, clofazimine, sodium sulfoxone, diaminodiphenylsulfone (DDS, dapsone)

5. Antifungal agents: amphotericin B, ketoconazole, clotrimazole, miconazole, econazole, natamycin, flucytosine, nystatine, griseofulvin



6. Antiviral agents: aciclovir, idoxuridine, amantidine, methisazone, cytarabine, vidarabine, ganciclovir
7. Chemotherapy of amebiasis: chloroquine, iodoquinol, clioquinol, metronidazole, dehydroemetine, paromomycin, diloxanide, furoatetinidazole, 5 emetine
8. Anti-malarial agents: chloroquine, pyrimethamine, hydroxychloroquine, quinine, mefloquine, sulfadoxine/pyrimethamine, pentamidine, sodium suramin, primaquine, trimethoprim, proguanil
9. Anti-helminthiasis agents: antimony potassium tartrate, niridazole, 10 antimony sodium dimercaptosuccinate, oxamniquine, bephenium, piperazine, dichlorophen, praziquantel, diethylcarbamazine, pyrantel pamoate, hycanthone, pyrivium pamoate, levamisole, stibophen, mebendazole, tetramisole, metrifonate, thiobendazole, niclosamide
10. Anti-inflammatory agents: acetylsalicylic acid, mefenamic acid, aclofenac, 15 naproxen, azopropanone, niflumic acid, benzydamine, oxyphenbutazone, diclofenac, piroxicam, fenoprofen, pirprofen, flurbiprofen, sodium salicylate, ibuprofensulindac, indomethacin, tiaprofenic acid, ketoprofen, tolmetin
11. Anti-gout agents: colchicine, allopurinol
12. Centrally acting (opoid) analgesics: alfentanil, methadone, bezitramide, 20 morphine, buprenorfine, nicomorphine, butorfanol, pentazocine, codeine, pethidine, dextromoramide, piritranide, dextropropoxyphene, sufentanil, fentanyl
13. Local anesthetics: articaine, mepivacaine, bupivacaine, prilocaine, etidocaine, procaine, lidocaine, tetracaine
- 25 14. Drugs for Parkinson's disease: amantidine, diphenhydramine, apomorphine, ethopropazine, benztropine mesylate, lergotril, biperiden, levodopa, bromocriptine, lisuride, carbidopa, metixen, chlorphenoxamine, orphenadrine, cycrimine, procyclidine, dexetimide, trihexyphenidyl



15. Centrally active muscle relaxants: baclofen, carisoprodol, chlormezanone, chlorzoxazone, cyclobenzaprine, dantrolene, diazepam, febarbamate, mefenoxalone, mephenesin, metoxalone, methocarbamol, tolperisone

## 16. Hormones and hormone antagonistics

5

### 16.1 Corticosteroids

16.1.1 *Mineralocorticosteroids*: cortisol, desoxycorticosterone, flurohydrocortisone

10

16.1.2 *Glucocorticosteroids*: beclomethasone, betamethasone, cortisone, dexamethasone, fluocinolone, fluocinonide, fluocortolone, fluorometholone, fluprednisolone, flurandrenolide, halcinonide, hydrocortisone, medrysone, methylprednisolone, paramethasone, prednisolone, prednisone, triamcinolone (acetonide)

15

### 16.2 Androgens

16.2.1 *Androgenic steroids used in therapy*: danazole, fluoxymesterone, mesterolone, methyltestosterone, testosterone and salts thereof

20

16.2.2 *Anabolic steroids used in therapy*: calusterone, nandrolone and salts thereof, dromostanolone, oxandrolone, ethylestrenol, oxymetholone, methandriol, stanozolol methandrostenolone, testolactone

16.2.3 *Antiandrogens*: cyproterone acetate

25

### 16.3 Estrogens

16.3.1 *Estrogenic steroids used in therapy*: diethylstilbestrol, estradiol, estriol, ethinylestradiol, mestranol, quinestrol



16.3.2 *Anti-estrogens*: chlorotrianisene, clomiphene, ethamoxytriphetol, nafoxidine, tamoxifen

16.4 *Progestins*: allylestrenol, desogestrel, dimethisterone, dydrogesterone, ethinylestrenol, ethisterone, ethynadiol diacetate, etynodiol, hydroxyprogesterone, levonorgestrel, lynestrenol, medroxyprogesterone, megestrol acetate, norethindrone, norethisterone, norethynodrel, norgestrel, progesterone

## 17. Thyroid drugs

17.1 Thyroid drugs used in therapy: levothyronine, liothyronine

17.2 *Anti-thyroid drugs used in therapy*: carbimazole, methimazole, methylthiouracil, propylthiouracil

When a non-peptide, non-protein, small-sized drug, such as those described above, is to be incorporated, the polyalkylene glycol terephthalate component of the copolymer preferably has a molecular weight of from about 200 to 400. Also, the polyalkylene glycol terephthalate component is present in the copolymer in an amount of from 20 wt.% to 90 wt.% of the weight of the copolymer, preferably from about 40 wt.% to about 70 wt.% of the weight of the copolymer. In general, the aromatic polyester is present in the copolymer in an amount of from 10 wt.% to 80 wt.% of the copolymer, preferably in an amount of from about 30 wt.% to about 60 wt.% of the copolymer.

When a hydrophobic small-sized drug, such as, for example, a steroid hormone is incorporated, preferably at least one hydrophobic antioxidant is present. Hydrophobic antioxidants which may be employed include, but are not limited to, tocopherols, such as  $\alpha$ -tocopherol,  $\beta$ -tocopherol,  $\gamma$ -tocopherol,  $\delta$ -tocopherol,  $\epsilon$ -tocopherol,  $\zeta_1$ -tocopherol,  $\zeta_2$ -tocopherol, and  $\eta$ -tocopherol; and 1-ascorbic acid 6-palmitate. Such hydrophobic antioxidants





retard the degradation of the copolymer and retard the release of the biologically active agent. Thus, the use of a hydrophobic or lipophilic antioxidant is applicable particularly to the formation of matrices which include drugs which tend to be released quickly from the coating, such as, for  
5 example, small drug molecules having a molecular weight less than 500. The at least one hydrophobic antioxidant may be present in the coating in an amount of from about 0.1 wt.% to about 10 wt.% of the total weight of the matrix, preferably from about 0.5 wt.% to about 2 wt.%.

When the coating includes a hydrophilic small-sized drug, such as  
10 an aminoglycoside, it may also include, in addition to the hydrophobic antioxidant, a hydrophobic molecule such as cholesterol, ergosterol, lithocholic acid, cholic acid, dinosterol, betuline, or oleanolic acid, which may be employed in order to retard the release rate of the agent from the copolymer coating. Such hydrophobic molecules prevent water penetration into the coating, but do  
15 not compromise the degradability of the coating. In addition, such molecules have melting points from 150°C to 200°C or decreases the coating diffusion coefficient for the biologically active agent, such as small drug molecule, to be released. Thus, such hydrophobic molecules provide for a more sustained release of a biologically active agent from the coating. The at least one  
20 hydrophobic molecule may be present in the coating in an amount of from about 0.1 wt.% to about 20 wt.%, preferably from 1.0 wt.% to 5.0 wt.%.

If it is desired to increase the hydrophilicity of the polymer, and thereby increase the degradation rate and drug releasing rate of the copolymer, the copolymer may be modified by partially replacing the aromatic  
25 moiety with an aliphatic moiety such as succinate and/or by replacing partially the alkylene with dioxyethylene. For example, terephthalate can be replaced by succinate in an amount of from about 0.1 mole% to about 20 mole%, preferably from about 0.1 mole% to about 5 mole%, by partially replacing dimethyl terephthalate as a starting component with dimethyl succinate. As  
30 another example, butylene is replaced with oxydiethylene in an amount of



from about 0.1 mole% to about 20 mole%, preferably from about 0.5 mole% to about 2 mole%, by replacing 1,4-butanediol with dimethyleneglycol as a starting component.

5        Examples of peptides or proteins which may advantageously be contained in the coating include, but are not limited to, immunogenic peptides or immunogenic proteins, which include, but are not limited to, the following:

*Growth factors:* bone morphogenetic proteins, transforming growth factors, fibroblast growth factors, epidermal growth factors, etc.

10        *Toxins:* diphtheria toxin, tetanus toxin

*Viral surface antigens or parts of viruses:* adenoviruses, Epstein-Barr Virus, Hepatitis A Virus, Hepatitis B Virus, Herpes viruses, HIV-1, HIV-2, HTLV-III, Influenza viruses, Japanese encephalitis virus, Measles virus, Papilloma viruses, Paramyxoviruses, Polio Virus, Rabies, Virus, Rubella Virus, Vaccinia (Smallpox) viruses, Yellow Fever Virus

15        *Bacterial surface antigens or parts of bacteria:* Bordetella pertussis, Helicobacter pylori, Clostridium tetani, Corynebacterium diphtheria, Escherichia coli, Haemophilus influenza, Klebsiella species, Legionella pneumophila, Mycobacterium bovis, Mycobacterium leprae, Mycobacterium tuberculosis, Neisseria gonorrhoeae, Neisseria meningitidis, Proteus species, Pseudomonas aeruginosa, Salmonella species, Shigella species, Staphylococcus aureus, Streptococcus pyogenes, Vibrio cholera, Yersinia pestis

20        *Surface antigens of parasites causing disease or portions of parasites:* Plasmodium vivax - malaria, Plasmodium falciparum - malaria, Plasmodium ovale - malaria, Plasmodium malariae - malaria, Leishmania tropica - leishmaniasis, Leishmania donovani, leishmaniasis, Leishmania braziliensis - leishmaniasis, Trypanosoma rhodescense - sleeping sickness, Trypanosoma gambiense - sleeping sickness, Trypanosoma cruzi - Chagas' disease, Schistosoma mansoni -

30



schistosomiasis, *Schistosomoma haematobium* - schistomiasis,  
*Schistosoma japonicum* - shichtomiasis, *Trichinella spiralis* - trichinosis,  
*Strongyloides duodenale* - hookworm, *Ancylostoma duodenale* -  
hookworm, *Necator americanus* - hookworm, *Wucheria bancrofti* -  
5 filariasis, *Brugia malaya* - filariasis, *Loa loa* - filariasis, *Dipetalonema*  
*perstans* - filariasis, *Dracuncula medinensis* - filariasis, *Onchocerca*  
*volvulus* - filariasis  
*Immunoglobulins*: IgG, IgA, IgM, Antirabies immunoglobulin,  
Antivaccinia immunoglobulin *Antitoxins*: Botulinum antitoxin,  
10 diphtheria antitoxin, gas gangrene antitoxin, tetanus antitoxin.

Other peptides or proteins which may be encapsulated include, but  
are not limited to, antigens which elicit an immune response against Foot and  
Mouth Disease, hormones and growth factors such as follicle stimulating  
15 hormone, prolactin, angiogenin, epidermal growth factor, calcitonin,  
erythropoietin, thyrotropic releasing hormone, insulin, growth hormones,  
insulin-like growth factors 1 and 2, skeletal growth factor, human chorionic  
gonadotropin, luteinizing hormone, nerve growth factor, adrenocorticotrophic  
hormone (ACTH), luteinizing hormone releasing hormone (LHRH),  
20 parathyroid hormone (PTH), thyrotropin releasing hormone (TRH),  
vasopressin, cholecystokinin, and corticotropin releasing hormone; cytokines,  
such as interferons, interleukins, colony stimulating factors, and tumor  
necrosis factors: fibrinolytic enzymes, such as urokinase, kidney plasminogen  
activator; and clotting factors, such as Protein C, Factor VIII, Factor IX, Factor  
25 VII and Antithrombin III. Examples of other proteins or peptides which may  
be encapsulated include, but are not limited to, albumin, atrial natriuretic  
factor, renin, superoxide dismutase,  $\alpha_1$ -antitrypsin, lung surfactant proteins,  
bacitracin, bestatin, cyclosporine, delta sleep-inducing peptide (DSIP),  
endorphins, glucagon, gramicidin, melanocyte inhibiting factors, neurotensin,  
30 oxytocin, somostatin, terprotide, serum thymide factor, thymosin, DDAVP,



dermorphin, Met-enkephalin, peptidoglycan, satietin, thymopentin, fibrin degradation product, des-enkephalin- $\alpha$ -endorphin, gonadotropin releasing hormone, leuprolide,  $\alpha$ -MSH, and metkephamid. It is to be understood, however, that the scope of the present invention is not limited to any specific  
5 peptides or proteins.

Before applying the coating, the surface to which it is to be applied is preferably cleaned or treated to remove any contaminants and to promote good adhesion of the coating. Various methods for cleaning may be employed. The metallic implants may be rinsed with a degreaser, *i.e.* acetone, alkyl  
10 alcohols, etc. and then thoroughly rinsed with pure water.

In order to improve coating adhesion, various surface treatments may be applied to metal implants. Mechanical surface treatments, such as sand-blasting, scoring, polishing and grinding can increase surface roughness of the implants and improve the bonding strength between the coatings and  
15 metal substrate. For similar purposes, chemical surface treatments may be also applied to metal substrates prior to coating. Among others chemical treatments available for metals, acid etchings will be preferred by treating implantable devices with strong mineral acids, such as hydrofluoric, hydrochloric, sulfuric, nitric and perchloric acids. It may also useful to treat  
20 the metal devices with oxidising agents such as nitric acid, peroxyhalogen acids, hydroxyperoxides, or hydrogen peroxide to form a fresh metal oxide layer. After the mechanical or chemical treatment, it is necessary to rinse the implants with pure water under ultrasound for removal of surface contaminants.

25 A coating according to the invention may be applied to a surface by methods known to those skilled in the art, like by brushing, spraying, wiping, dipping, extruding or injecting. The latter three methods are preferred when porous structures or fibrous meshes are to be coated. Use of these methods allows penetration of the copolymer of which the coating is formed inside the





pores of the devices and a (uniform) coating of the total surface area. Brushing and spraying are preferred in case of non-porous devices.

If desired, organic solvents may be used to dissolve the copolymer. Suitable solvents are chloroform, dichloromethane, N-methyl-2-pyrrolidone, 5 dimethyl sulfoxide, acetone, hexafluoroisopropanol and the like. The selection of a suitable solvent will be dependent on the composition of the chosen copolymer. Alternatively, heat may be applied to process a copolymer of which a coating is to be formed.

A biologically active agent may be incorporated into the coating by 10 dissolving it in the copolymer solution of which the coating is formed. Hence, a homogeneous solution is formed or a suspension is formed by dispersion. Alternatively, a solution of a biologically active agent may be mixed with the copolymer solution to form a homogeneous mixture, or an emulsion. Also, a biologically agent can be incorporated by physically mixing with the 15 copolymer, for example by extrusion. Since in the latter case heat is applied, care must be taken not to harm the stability and/or activity of the biologically active agent.

If it is desired that a porous coating is formed, a pore-forming agent can be included in the solution or suspension of the copolymer from which the 20 coating is formed. Pore-forming agents may include organic solvents, water, salts (sodium chloride, sodium citrate, and the like), sugars and water-soluble synthetic polymers. Using such pore-forming agents, pores can be created by leaching-out of the agent, or by phase separation.

The thickness of the coatings of this invention may range from a few 25 microns up to any desired thickness (up to a few hundred microns). The thickness of the coating may be adjusted by the viscosity of the copolymer solution that is used to prepare the coating. The viscosity of the copolymer solution may be adjusted by parameters like the molecular weight of the copolymer, the copolymer concentration in the solution, the selected solvent,



the temperature, etc. In case of spraying or brushing, spraying time and flow rate may also influence the thickness of the coating.

The invention will be further elucidated by the following, non-restrictive example.

5

#### Example

A porous scaffold was produced as described in example 1 of European patent application 01200328.1, the contents of which are incorporated herein by reference, from a copolymer of polyethylene glycol (PEG, MW = 300 g/mole) and polybutylene terephthalate (PBT), wherein the weight percentage PBT was 55 %. The porosity of the scaffold was approximately 77 v/v%. About 400 mg of the scaffold to be coated was placed on a grid that was connected to a vacuum pump (see figure 1 for a schematic representation).

15 The coating emulsion was prepared by mixing a protein solution (1.0 ml, 50 mg lysozyme per ml phosphate buffered saline (PBS), pH 7.4) with a polymer solution (6 ml chloroform, 1g copolymer of polyethylene glycol (PEG, MW = 1000 g/mole) and polybutylene terephthalate (PBT), wherein the weight percentage PBT was 30 %.) using ultra-turrax mixing (30 s at 19 krpm, Ika Labortechnik T25). The resulting water-in-oil emulsion was poured on top of the scaffold, and a vacuum of 300 Torr was applied for 5 minutes. Thereafter, the scaffolds were dried overnight under vacuum at room temperature.

To evaluate the release of lysozyme from the coated scaffolds, pieces of approximately 75 mg were incubated in 1 ml PBS (pH 7.4). Vials were continuously shaken at 37°C and samples were taken at various time points. The protein concentration in the buffer solution was determined using a standard Coomassie Blue assay (Pierce). In figure 2, the release of lysozyme from the coated scaffolds is presented.

25



Claims

1. A coating for a medical device comprising a copolymer of a polyalkylene glycol terephthalate and an aromatic polyester.
2. A coating according to claim 1, wherein the polyalkylene glycol is chosen from the group of polyethylene glycol terephthalate, polypropylene glycol terephthalate, and polybutylene glycol terephthalate.
3. A coating according to claim 2, wherein the polyalkylene glycol is polyethylene glycol terephthalate.
4. A coating according to any of the preceding claims, wherein the polyester is chosen from the group of polyethylene terephthalate, polypropylene terephthalate, and polybutylene terephthalate.
5. A coating according to claim 4, wherein the polyester is polybutylene terephthalate.
6. A coating according to any of the preceding claims, wherein the copolymer comprises 20-90 wt.%, preferably 40-70 wt.%, based on the weight of the copolymer, of the polyalkylene glycol.
7. A coating according to any of the preceding claims, wherein the weight average molecular weight of the polyalkylene glycol is from about 150 to about 4000, preferably from about 200 to about 1500.
8. A coating according to any of the preceding claims, wherein the weight average molecular weight of the copolymer lies between about 10,000 and about 300,000, preferably between about 40,000 and about 120,000.
9. A coating according to any of the preceding claims further comprising an additive.
10. A coating according to claim 9, wherein the additive is a biologically active agent chosen from the group of antimicrobial agents, such as antibacterial and anti-fungal agents, anti-viral agents, anti-tumor agents, immunogenic agents, lipids, lipopolysaccharides, hormones and growth factors.



11. A coating according to claim 9, wherein the additive is a biologically active agent is chosen from the group of peptides, oligopeptides, polypeptides and proteins.
12. A coating according to any of the preceding claims, applied to a surface  
5 chosen from the group of metals, metal alloys, ceramics, glasses and polymeric materials.
13. A coating according to claim 12, wherein the surface is a surface of a medical device chosen from the group of catheters, stents, fibres, non-woven fabrics, vascular grafts, porous metals for e.g. acetabulum revision, and porous  
10 scaffolds for tissue engineering.
14. A coating according to any of the preceding claim, which is porous.
15. A method for applying a coating according to any of the preceding claims to a surface, comprising brushing, spraying, wiping, dipping, extruding or injecting.
- 15 16. A method according to claim 15, wherein the surface is cleaned and/or subjected to a mechanical treatment prior to application of the coating.
17. A method according to claim 15 or 16, wherein the coating is applied from a solution or suspension of the copolymer.
18. A method according to claim 17, wherein a biologically active agent is  
20 included in the solution or suspension.
19. A method according to claim 17 or 18, wherein a pore-forming agent is included in the solution or suspension.
20. A medical device comprising a coating according to any of the claims 1-13.
- 25 21. A medical device according to claim 20 chosen from the group of catheters, fibres, non-woven fabrics, vascular grafts, porous metals for e.g. acetabulum revision, dental filling materials, materials for approximation, adhesion of tissues, materials used in osteo-synthesis (e.g. pins or bone screws), cardiac patches, sutures, soft and hard tissue scaffolds and fillers (e.g.  
30 collagen, calcium phosphate, bioglass), stents, bone void fillers intended for the





repair of bone defects, intrauterine devices, root canal fillers, drug delivery pumps, implantable infusion pumps, spacer devices, implants containing medicinal products, and scaffolds for tissue engineering.



Title: Coating for medical devices

Abstract

The invention relates to a coating for medical devices. The coating comprises a specific copolymer of which the composition may be adjusted such as to achieve an excellent adhesion to a wide range of surfaces. The coating may further comprise an additive, such as a biologically active agent, which may be released *in vivo* in a controlled manner, as the degradability of the coating may also be adjusted to a predetermined rate. The invention further relates to a process for applying the coating to a surface and to a medical device comprising the coating.



1/2




Figure 1: Principle of coating of a porous scaffold using an protein containing emulsion.






Figure 2: Release of lysozyme from coated scaffolds

